|
Hyperglycemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
[6]-Gingerol, from Zingiber officinale, potentiates GLP-1 mediated glucose-stimulated insulin secretion pathway in pancreatic β-cells and increases RAB8/RAB10-regulated membrane presentation of GLUT4 transporters in skeletal muscle to improve hyperglycemia in Lepr<sup>db/db</sup> type 2 diabetic mice.
|
28793909 |
2017 |
|
Hyperglycemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
We investigated whether oral administration of human commensal bacteria engineered to secrete GLP-1(1-37) could ameliorate hyperglycemia in a rat model of diabetes by reprogramming intestinal cells into glucose-responsive insulin-secreting cells.
|
25626737 |
2015 |
|
Hyperglycemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
We hypothesized that the downregulation of GLP-1R by hyperglycemia might reduce the renal-protective effects of GLP-1R agonists in diabetic nephropathy (DN).
|
31136032 |
2019 |
|
Hyperglycemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
We analyzed the impact of PARP-1 inhibition on <i>C. elegans</i> health in the setting of hyperglycemia and on glucose-stimulated GLP-1 secretion in human intestinal cells.
|
29392078 |
2018 |
|
Hyperglycemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
Treatment with an N2 supplement in combination with three soluble factors (glucagon-like peptide-1 [GLP-1] receptor agonist, notch inhibitor, and transforming growth factor-β [TGF-β] inhibitor) enhanced liver-to-pancreas transdifferentiation based on the following findings: i) the incidence of c-peptide-positive cells increased by approximately 1.2-fold after the aforementioned treatment; ii) the c-peptide expression level in the treated cells increased by approximately 12-fold as compared with the level in the untreated cells; iii) the treated cells secreted insulin in a glucose-dependent manner, whereas the untreated cells did not; and iv) transplantation of treated-transdifferentiated cells into streptozotocin-induced immunodeficient diabetic mice led to the amelioration of hyperglycemia.
|
29768476 |
2018 |
|
Hyperglycemia
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
To investigate alterations in gene expression resulting from incubation with GLP-1 (7-36) or hyperglycaemia, the RNA expression levels of miR-23a, PGC-1α, Bak, Bax and UCP2 were quantified using real-time PCR.
|
26315270 |
2015 |
|
Hyperglycemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
To evaluate whether exposure to GLP-1 receptor agonist Liraglutide could modulate pro-atherogenic alterations previously observed in endothelial cells obtained by women affected by gestational diabetes (GD), thus exposed in vivo to hyperglycemia, oxidative stress, and inflammation and to evaluate endothelial microvesicle (EMV) release, a new reliable biomarker of vascular stress/damage.
|
28753251 |
2017 |
|
Hyperglycemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
This study aims to erase the likelihood of hyperglycaemia and to remain the inherent catabolic effects through improving GLP-1R activation and deteriorating GCGR activation so as to lower the bodyweight and show diabetes-protective effects.
|
28772236 |
2017 |
|
Hyperglycemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
These characteristics make GLP-1 receptor agonists attractive agents to treat dysglycaemia in perioperative or high-dependency hospital settings, where glycaemic variability and hyperglycaemia are associated with poor prognosis.
|
31141838 |
2019 |
|
Hyperglycemia
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
There is no evidence that the GLP-1R agonists cause a major reduction in HbA1c, or have a major effect on hypo- or hyperglycemia in subjects with TD1M.
|
30234389 |
2018 |
|
Hyperglycemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
There have been several new treatment approaches established for the management of hyperglycemia in type 2 diabetes (T2D), with treatment guidelines listing both glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and basal insulin therapies as considerations for patients who have failed to control their blood glucose with oral antidiabetic agents.
|
29492243 |
2018 |
|
Hyperglycemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
The observation that the insulinotropic actions of GLP-1 are reduced in type 2 diabetes mellitus (T2DM) led to the development of incretin-based therapies - GLP-1 receptor agonists and dipeptidyl peptidase 4 (DPP-4) inhibitors - for the treatment of hyperglycaemia in these patients.
|
28869249 |
2017 |
|
Hyperglycemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
The implications of these findings are very important for the management of type 2 diabetes given that GLP-1 receptor agonist are currently approved for the treatment of hyperglycemia and glucagon receptor antagonists and GLP-1/glucagon dual agonists are under development.
|
28463898 |
2017 |
|
Hyperglycemia
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Sitagliptin, a dipeptidyl peptidase-IV inhibitor (DPP-4), sustains activity of the incretin hormones GLP-1 and GIP and improves hyperglycemia in Type 2 diabetes mellitus (T2DM).
|
29138226 |
2018 |
|
Hyperglycemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
Single-cell digital PCR revealed GLP-1 receptor expression in neurogliaform cells and showed that copy numbers of mRNA of the Glp1r gene in hyperglycaemia exceeded those in hypoglycaemia by 9.6 times (p < 0.008).
|
30637442 |
2019 |
|
Hyperglycemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
Pasireotide-induced hyperglycemia occurs early, within the first 3 months of treatment, due to a decrease in insulin secretion secondary to a fall in secretion of GLP-1 and GIP, and potentially also due to a direct inhibitory effect of pasireotide on beta cells.
|
28579289 |
2017 |
|
Hyperglycemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
Our results identify D-allulose as prominent GLP-1 releaser that acts via vagal afferents to restrict feeding and hyperglycemia.
|
29317623 |
2018 |
|
Hyperglycemia
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Nevertheless, chronic treatment of diabetic mice with P5 increased adipogenesis, reduced adipose tissue inflammation as well as hepatic steatosis and was more effective at correcting hyperglycaemia and lowering haemoglobin A1c levels than Exendin-4, suggesting that GLP-1R G-protein-biased agonists may provide a novel therapeutic approach to T2DM.
|
26621478 |
2015 |
|
Hyperglycemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
Moreover, ursolic acid is more effective than betulinic acid in reduction of hyperglycemia and increase of GLP-1 secretion.
|
28756460 |
2017 |
|
Hyperglycemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
Incretin hormones (glucagon-like peptide-1 [GLP-1] and gastric inhibitory polypeptide [GIP]) may play a role in the development of glucose intolerance and hyperglycemia in patients with hyperthyroidism.
|
28452237 |
2017 |
|
Hyperglycemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
In view of the predisposition of patients with chronic hyperglycaemia to glucagon-like peptide 1 receptor (GLP-1R) downregulation and the lag time to optimal efficacy of GLP-1R agonists, we propose that patients should have C-peptide levels measured to determine the risk of ketosis and whether insulin should be continued with dose adjustments when starting a GLP-1R agonist.
|
28710307 |
2017 |
|
Hyperglycemia
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
In this study, fecal microbiota transplantation (FMT) using fecal material from metformin-treated mice was found to upregulate the expression of GLP-1 and pattern-recognition receptors TLR1 and TLR4 for the improvement in hyperglycemia caused by a high-fat diet.
|
31501716 |
2019 |
|
Hyperglycemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
In contrast, Zac1 expression did not interfere with the signaling of the glucagon-like peptide 1 receptor (GLP-1R), and the GLP-1 analog liraglutide improved hyperglycemia in transplanted experimental diabetic mice.
|
22547676 |
2012 |
|
Hyperglycemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
In clinical practice, they are also classified as basal or prandial GLP-1 receptor agonists to differentiate between patients who would benefit more from one or another based on characteristics such as previous treatment and the predominance of fasting or postprandial hyperglycemia.
|
28115994 |
2017 |
|
Hyperglycemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
Glucagonlike peptide 1 (GLP-1) receptor agonists have been efficacious for the treatment of type 2 diabetes due to their ability to reduce weight and attenuate hyperglycemia.
|
29905825 |
2018 |